Vemurafenib
KT Flaherty, U Yasothan, P Kirkpatrick - Nature reviews Drug discovery, 2011 - go.gale.com
KT Flaherty, U Yasothan, P Kirkpatrick
Nature reviews Drug discovery, 2011•go.gale.comIn August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase,
was approved by the US Food and Drug Administration (FDA) for the treatment of patients
with unresectable or metastatic melanoma with the [BRAF. sup. V600E] mutation.Until
recently, the prognosis for patients with advanced melanoma was very poor, with the
estimated median survival time for patients with stage IV metastatic melanoma being less
than a year1. There were only two FDA-approved drugs for such patients--the cytotoxic …
was approved by the US Food and Drug Administration (FDA) for the treatment of patients
with unresectable or metastatic melanoma with the [BRAF. sup. V600E] mutation.Until
recently, the prognosis for patients with advanced melanoma was very poor, with the
estimated median survival time for patients with stage IV metastatic melanoma being less
than a year1. There were only two FDA-approved drugs for such patients--the cytotoxic …
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the [BRAF. sup. V600E] mutation.
Until recently, the prognosis for patients with advanced melanoma was very poor, with the estimated median survival time for patients with stage IV metastatic melanoma being less than a year1. There were only two FDA-approved drugs for such patients--the cytotoxic alkylating agent dacarbazine and high-dose interleukin-2--both of which are associated with responses in only a small proportion of patients, and neither of which have been shown to have a substantial impact on overall survival (1).
Gale